Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy

This study is currently recruiting participants.
Verified November 2011 by Xijing Hospital
Sponsor:
Information provided by (Responsible Party):
Xijing Hospital
ClinicalTrials.gov Identifier:
NCT01372891
First received: June 10, 2011
Last updated: November 21, 2011
Last verified: November 2011

June 10, 2011
November 21, 2011
April 2010
April 2013   (final data collection date for primary outcome measure)
increase in SCr 0.5 mg/dL(44.2 mol/L) from baseline [ Time Frame: 3 days ] [ Designated as safety issue: No ]
samples will be collected at 24, 48 and 72 hours after PCI
Same as current
Complete list of historical versions of study NCT01372891 on ClinicalTrials.gov Archive Site
a 25% increase in SCr from baseline [ Time Frame: 3 days ] [ Designated as safety issue: No ]
samples will be collected at 24, 48 and 72 hours after PCI.
Same as current
Not Provided
Not Provided
 
Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy
Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy

The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.

Contrast induced nephropathy (CIN) is a severe complication after percutaneous coronary intervention (PCI). CIN is responsible for approximately genic renal insufficiency and is the third cause of hospital-acquired renal failure and the injury of endothelial of renal tubule is responsible for the CIN. However markers reliably identifying CIN in the patients undergoing PCI are rare. Adiponectin is a 30-kDa adipocyte-derived vasoactive peptide closely linked to components of the metabolic syndrome. Recent study demonstrates that the quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events. Therefore, the investigators presume that the adiponectin excretion may predict the incidence of the CIN. The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of CIN in the patients undergoing PCI.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

serum,urine

Probability Sample

This study enrolls a group of patients> 18 who have ST elevation myocardial infarction (STEMI) undergoing primary PCI.

Myocardial Ischemia
Not Provided
Patients underging PCI
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
December 2014
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients > 18 of age who are undergoing elective PCI and are able to give informed consent are eligible for study.

Exclusion Criteria:

  • The end-stage renal failure
  • The patients who are relieving dialysis
Both
18 Years to 80 Years
No
Contact: Ling Tao, M.D Ph.D +86-15002955798 lingtao2006@gmail.com
China
 
NCT01372891
xjyy110502
No
Xijing Hospital
Xijing Hospital
Not Provided
Not Provided
Xijing Hospital
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP